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The vast majority of the peptides presented by 
MHC molecules are derived from self-proteins 
and do not activate mature T cells. Antigen 
recognition and T cell activation must thus be 
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Recent work has demonstrated that nonstimulatory endogenous peptides can enhance T cell 
recognition of antigen, but MHCI- and MHCII-restricted systems have generated very differ-
ent results. MHCII-restricted TCRs need to interact with the nonstimulatory peptide–MHC 
(pMHC), showing peptide specificity for activation enhancers or coagonists. In contrast, the 
MHCI-restricted cells studied to date show no such peptide specificity for coagonists, sug-
gesting that CD8 binding to noncognate MHCI is more important. Here we show how this 
dichotomy can be resolved by varying CD8 and TCR binding to agonist and coagonists coupled 
with computer simulations, and we identify two distinct mechanisms by which CD8 influences 
the peptide specificity of coagonism. Mechanism 1 identifies the requirement of CD8 binding 
to noncognate ligand and suggests a direct relationship between the magnitude of coagonism 
and CD8 affinity for coagonist pMHCI. Mechanism 2 describes how the affinity of CD8 for 
agonist pMHCI changes the requirement for specific coagonist peptides. MHCs that bind CD8 
strongly were tolerant of all or most peptides as coagonists, but weaker CD8-binding MHCs 
required stronger TCR binding to coagonist, limiting the potential coagonist peptides. These 
findings in MHCI systems also explain peptide-specific coagonism in MHCII-restricted cells, as 
CD4–MHCII interaction is generally weaker than CD8–MHCI.
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Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
tuned to allow for recognition of the small 
minority of disease-associated peptide–MHC 
(pMHC) “needles in the haystack” of nonstim-
ulatory endogenous pMHC (Davis et al., 2007; 
Gascoigne, 2008; Gascoigne et al., 2010). Sev-
eral experiments have shown that T cell activa-
tion by small amounts of antigen is enhanced 
by the presence of endogenous peptides (Irvine 
et al., 2002; Yachi et al., 2005). Although this 
activation enhancement or coagonist phenom-
enon has been reported for both MHC class I 
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MHC, TCR, and coreceptor interactions. Here, an extension 
of this model allows us to describe coagonism enabled by self-
peptides, taking into account the distinct activation states of 
Lck (Nika et al., 2010; Stirnweiss et al., 2013).
Because of the glaring discrepancies in the requirements 
for TCR discrimination between coagonist peptides in MHCI- 
and MHCII-restricted systems, there is a need for a unifying 
concept to explain activation enhancement for both T cell 
lineages. In this paper, we used H-2Kb and H-2Db single 
chain (sc)–pMHCs (Yu et al., 2002; Choudhuri et al., 2005; 
Palmowski et al., 2009), which allowed us to dissect the dis-
tinct contributions of CD8 affinity and of TCR affinity for 
both antigenic and nonstimulatory pMHCs. Using H-2Kb– 
and H-2Db–restricted TCRs and stochastic computer simula-
tions of the kinetics of T cell activation, we describe two 
distinct mechanisms by which CD8 affinity for pMHC can 
influence the requirements for coagonists. Mechanism 1 de-
scribes CD8 binding to nonstimulatory pMHC as an absolute 
requirement for coagonism and shows that higher-affinity 
CD8–pMHC interactions can mitigate peptide specificity re-
quirements for coagonists and increase the magnitude of en-
hancement. Mechanism 2 describes how the affinity of CD8 
for agonist pMHC influences the requirements for TCR in-
teraction with coagonist pMHC. A relatively simple kinetic 
model of T cell activation is sufficient to account for all coag-
onist phenomena, thus unifying disparate observations from 
CD4 and CD8 T cells.
RESULTS
Development of inducible, antigenic, sc-MHC  
Chinese hamster ovary (CHO) cell expression systems
sc-pMHCI molecules are produced by recombinant con-
structs in which the MHC-binding peptide is linked to the 
N terminus of 2-microglobulin, which in turn is linked to 
the N terminus of the MHCI heavy chain (Yu et al., 2002; 
Choudhuri et al., 2005; Palmowski et al., 2009). When ex-
pressed on the cell surface, these sc-MHCI constructs are very 
stable and can act as potent agonists for T cells. sc-KbOVA 
(OVA peptide 257–264, SIINFEKL, on H-2Kb, recognized 
by OT-I TCR; Hogquist et al., 1994) and sc-DbNP68 (influ-
enza A/NT/60/68 nucleoprotein 366–374, ASNENMDAM, 
on H-2Db, recognized by F5 TCR; Townsend et al., 1986; 
Mamalaki et al., 1992) in doxycycline-inducible vectors were 
transfected into CHO Trex cells (expressing tetracycline re-
pressor). Doxycycline strongly up-regulated cell surface ex-
pression of sc-MHCI, allowing the CHO cells to stimulate 
antigen-specific T cell activation, as measured by CD69 up-
regulation or TCR endocytosis (Fig. 1). In the repressed state 
(absence of doxycycline), “leaky” expression of sc-KbOVA or 
sc-DbNP68 presented enough agonist to the CD8 OT-I or 
F5 T cells to induce some CD69 up-regulation but not 
enough to induce significant TCR down-regulation (Fig. 1, 
B and D). Expression of sc-KbOVA in the repressed state was 
virtually undetectable by flow cytometry with a KbOVA-specific 
antibody (Fig. 1 A; and not depicted; Porgador et al., 1997), 
(MHCI)–restricted T cells and thymocytes (Yachi et al., 2005, 
2007; Anikeeva et al., 2006; Juang et al., 2010) and for MHCII-
restricted T cells (Irvine et al., 2002; Li et al., 2004; Krogsgaard 
et al., 2005), the relative importance of TCR recognition of 
the endogenous pMHC appears to be very different for 
CD4 and CD8 T cells (Davis et al., 2007; Gascoigne, 2008; 
Gascoigne et al., 2010).
The number of potential coagonist peptides for a given 
CD4 T cell are very limited (Krogsgaard et al., 2005; Ebert 
et al., 2009; Lo et al., 2009), whereas coagonism for CD8 T cells 
or thymocytes occurs with a wide range of different non-
stimulatory peptides (Yachi et al., 2005, 2007; Juang et al., 
2010). This evidence thus suggests that MHCII-restricted TCRs 
discriminate between endogenous peptides, whereas MHCI-
restricted TCRs do not. However, recent data indicate that 
nonstimulatory pMHCI ligands show a very weak but possibly 
biologically significant interaction with TCR (Juang et al., 
2010). This suggested that TCRs might play a role in coagonism 
in MHCI-restricted cells but that its specificity is only evident 
for very weakly stimulatory TCR ligands such as those in-
volved in positive selection.
The CD8 coreceptor’s interaction with nonstimulatory 
MHCI has been suggested to be important for coagonism in 
MHCI-restricted cells (Yachi et al., 2005; Gascoigne, 2008; 
Gascoigne et al., 2010). Nonstimulatory pMHC alone can 
recruit CD8 to the T cell–APC interface (Yachi et al., 2005; 
Rybakin et al., 2011). Also, coagonist pMHCs became antag-
onists in CD8-negative cells (Stone et al., 2011). These results, 
along with the lack of peptide specificity for coagonists, sug-
gest that non-cognate CD8 coreceptor binding to nonsti-
mulatory pMHC is the dominant mechanism of activation 
enhancement for MHCI-restricted T cells. In addition, CD8 
affinity for the MHC presenting the antigenic peptide (ago-
nist) plays a direct role in signaling through the TCR, where 
increasing the affinity of CD8 can increase ligand potency 
and even bypass peptide specificity requirements altogether 
(Laugel et al., 2007; Wooldridge et al., 2007, 2010). Because 
there is a range of affinities for CD8 binding to different 
MHCI molecules (Cole et al., 2012), the relative require-
ments for CD8, or for TCR interaction with the nonstimula-
tory ligand, might be expected to vary with the strength of 
CD8–MHC binding. Interestingly, the two mouse MHCI-
restricted TCR models that have been analyzed in coago-
nism experiments (OT-I [Yachi et al., 2005, 2007; Juang 
et al., 2010] and 2C [Stone et al., 2011]) recognize H-2Kb or Ld, 
which show relatively high-affinity CD8 binding (Cole 
et al., 2012).
A stochastic, computational model has been used to inves-
tigate the role of coreceptors in TCR triggering, and results 
suggest that CD8 plays a dual role of stabilizing the TCR–
pMHC interaction and of delivering the CD8-associated 
kinase Lck to the TCR to initiate signaling, with the latter ef-
fect being the more important (Artyomov et al., 2010). This 
model explicitly combined two key features, membrane-protein 
mobility and protein–protein interactions (Lis et al., 2009), which 
allowed incorporation of many biophysical measurements for 
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Anikeeva et al., 2006; Gascoigne, 2008). To test this hypothesis, 
we generated D227K-E229K mutations, which are known to 
abrogate CD8 binding (Connolly et al., 1988, 1990; Potter et al., 
1989), in the sc-KbVSV and sc-DbUTY 3 domains. When 
super-transfected into inducible KbOVA-expressing cells 
(Fig. 3 A), we found that the sc-KbVSV CD8-binding mutant 
(sc-KbVSV-CD8m) did not provide coagonism to OT-I T cells 
(Fig. 3 B) or preselection thymocytes (not depicted). Simi-
larly, sc-DbUTY-CD8m expressed with repressed sc-DbNP68 
did not provide coagonism for F5 cells (Fig. 3, C and D). Un-
expectedly, the sc-DbUTY-CD8m had a mild and statistically 
significant inhibitory effect on F5 activation. These results re-
vealed that the intact CD8-binding site is absolutely required 
for coagonism in both OT-I and F5 systems.
We also tested the ability of known H-2Kb–binding pep-
tides (Santori et al., 2002; Yachi et al., 2005) to act as coago-
nists for F5 T cells. We used RMA-S cells as APCs, as these cells 
express very few MHCI molecules unless exogenous peptide 
is provided (Ljunggren et al., 1990; Yachi et al., 2005, 2007). 
When H-2Kb–binding peptides Slc2a3 (VNTIFTVV), Nmt1 
(AAYSFYNV), OVA, Stat3 (ATLVFHNL), and VSV were 
loaded on RMA-S cells pretreated with trace NP68 agonist 
peptide, we found that all peptides acted as strong coagonists 
for F5 CD8+ T cells (Fig. 3, E and F).
A computational model of T cell activation  
describes coagonism
Various computational and conceptual studies have dealt 
with the principles behind coagonism (Li et al., 2004; Wylie 
et al., 2007; Feinerman et al., 2008), but there has not yet 
been a treatment that simultaneously incorporates the diffu-
sion, binding, and reactions of proteins in space and time with 
many available biophysical measurements. However, such ki-
netic models have been used to describe the different depen-
dencies of T cell activation on CD4 and CD8 coreceptors 
whereas repressed sc-DbNP68 was detectable above back-
ground (Fig. 1 C).
Both H-2Kb and H-2Db nonstimulatory pMHCs  
can be coagonists
CHO cells expressing inducible sc-KbOVA or sc-DbNP68 
were super-transfected with nonstimulatory sc-MHCI con-
structs, enabling coexpression of agonist and nonstimulatory 
pMHC on the same cell (Fig. 2). This allowed us to probe co-
agonism by nonstimulatory peptides presented on H-2Kb and 
H-2Db, with both H-2Kb– and H-2Db–restricted TCRs. 
KbVSV (RGYVYQGL) and DbUTY (WMHHNMDLI) are 
nonstimulatory pMHCs for both OT-I and F5 T cells. We 
found that sc-KbVSV provided strong coagonism for both 
OT-I and F5 T cells, measured as CD69 up-regulation or IL2 
secretion (Fig. 2, B–D and F–H, respectively), or by phos-
phorylation of the NF-B precursor p-p105 (not depicted). 
sc-DbUTY also provided activation enhancement for both 
TCR transgenic T cells, but this was much weaker than the 
sc-KbVSV effect and did not show statistically significant co-
agonism of IL2 secretion. Nonstimulatory sc-DbNP68 also 
gave weak coagonism for OT-I T cells (not depicted). Analo-
gous activation results were obtained with preselection OT-I 
thymocytes stimulated with KbOVA-expressing CHO cells 
(not depicted). These data demonstrate that both H-2Kb  
and H-2Db nonstimulatory pMHC molecules were capable 
of being coagonists for TCRs restricted by the same or an-
other MHCI, but H-2Kb provided much stronger coagonism 
than H-2Db.
CD8 binding to nonstimulatory pMHC is directly  
related to the magnitude of coagonism
The lack of peptide specificity in coagonism in MHCI- 
restricted T cells could be the result of noncognate CD8 inter-
action with nonstimulatory MHCI molecules (Yachi et al., 2005; 
Figure 1. Expression of inducible sc-MHCI 
agonist molecules KbOVA and DbNP68 in 
CHO cells and activation of corresponding 
OT-I and F5 CD8 T cells. (A) Trex CHO cells 
expressing dox-inducible sc-MHC were stained 
with anti-Kb and analyzed by flow cytometry. 
Gray shading: untransfected Trex CHO cells. 
Purple: repressed (no dox) sc-KbOVA. Green: 
induced (+dox) sc-KbOVA. (B) OT-I T cells were 
incubated with the indicated CHO cell APCs for 
3 h, and TCR endocytosis (anti-V2; left) and 
CD69 expression (right) were assessed by flow 
cytometry. The horizontal black line indicates 
the CD69hi gate. The color coding is the same 
as in A. (C and D) As in A and B except CHO 
cells expressing dox-inducible sc-DbNP68 
were stained with anti-Db or exposed to F5 
responder T cells. TCR staining was by anti-
CD3. Data are representative of three inde-
pendent experiments.
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model to be consistent with these binding data. The TCR on 
rate for nonstimulatory peptides for both OT-I and F5 simu-
lations was set to the OT-I value for KbOVA so that we could 
directly compare nonstimulatory peptides with equal affinity 
and kinetics. We developed this model (see Supplemental 
text) that describes signal enhancement caused by the coexis-
tence of agonist and nonstimulatory peptides on the APC 
surface (Fig. 3 G). This model also describes increased TCR 
signaling in response to nonstimulatory ligands with higher 
CD8-binding affinities in both F5 and OT-I model systems 
(Fig. 3 H). This computational result is consistent with the 
following data: Fig. 2 showing a greater magnitude of en-
hancement by H-2Kb compared with H-2Db nonstimulatory 
pMHC, Fig. 3 (B and D) showing the absolute dependence of 
(Artyomov et al., 2010). We applied this formalism to a descrip-
tion of coagonism, incorporating separate on and off rates for 
TCR binding to agonist versus nonstimulatory pMHCI. The 
OT-I TCR has approximately twofold higher affinity for ago-
nist pMHCI than F5 (Kd of 5.9–6.5 µM for OT-I [Alam et al., 
1996, 1999] versus 11 µM for F5 [Willcox et al., 1999]). The 
kinetics describing these equilibrium constants are markedly 
different. The on and off rates for OT-I TCR–binding KbOVA 
are well characterized (3,720/M/s and 0.022/s, respectively; 
Alam et al., 1999). We calculated the on rate for the F5 TCR 
for DbNP68 based on the off rate and equilibrium affinity 
reported in the literature (koff = 0.8/s, Kd = 11 µM, kon = 
72,727/M/s, calculated; Willcox et al., 1999). Therefore, we 
varied the TCR kinetics for agonist pMHC in the kinetic 
Figure 2. Coagonism of OT-I and F5 CD8 
T cells by both sc-H-2Kb and sc-H-2Db 
nonstimulatory sc-MHCI. Inducible  
sc-KbOVA or sc-DbNP68 CHO cells were super-
transfected with constitutive sc-KbVSV or  
sc-DbUTY and used as APCs to assess coago-
nism of OT-I and F5 T cells. CHO cell APCs were 
stained for MHCI expression and in parallel 
exposed to responder T cells whose activation 
status was measured either by flow cytometry 
or IL2 ELISA. Inducible sc-KbOVA APCs and OT-I 
responder T cells are described in the top pan-
els, whereas inducible sc-DbNP68 APC and F5 
responder T cells are described in the bottom 
panels. (A and E) Analysis of Kb or Db expres-
sion on CHO cell APCs. Color coding is as 
shown in the y-axis labels of the bar graphs. 
In A, sc-DbUTY-YFP fusion construct was used 
to transfect cells expressing repressed KbOVA, 
and the YFP fluorescence was used here to 
report on sc-DbUTY expression relative to 
untransfected CHO cells (black). In the re-
maining panels, sc-MHCI expression was 
analyzed by antibody staining. (B and F)  
OT-I (B) and F5 (F) CD8 T cell expression of 
CD69 after incubation with the correspond-
ing CHO APCs from A or E, respectively. 
Horizontal black lines indicate the CD69hi 
gate. (C and G) Bar graphs represent mean ± 
SEM values of CD69hi cells for OT-I (C) and 
F5 (G). (D and H) IL2 production after 8 h of 
exposure to CHO cell APCs as indicated for 
OT-I (D) and F5 (H). Statistical significance 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001) results 
are from ANOVA analysis with Dunnett’s 
post-test, referencing the repressed agonist 
sample as the standard. For the OT-I CD69 
bar graph in C, n = 8 (individual mice) after 
removing outliers as defined by values >1.25 
times the interquartile distance. For D, n = 4; 
G, n = 6 (individual mice); H, n = 6. Each 
data panel is representative of three inde-
pendent experiments except C and G, which 
report the combined results from three inde-
pendent experiments.
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nonstimulatory Kb ligand (Juang et al., 2010). To probe the 
role of TCR interaction with the nonstimulatory ligands in 
coagonism using the sc-MHCI system, we used several strat-
egies. Residues in the 12-helices of MHCI comprise the 
main recognition structures for TCR CDR1 and CDR2 (Sun 
et al., 1995; Sim et al., 1998; Garcia et al., 2009). The E166K 
mutation disrupts recognition of KbVSV by VSV-specific CTL 
(Sun et al., 1995) and of KbOVA by OT-I CTL (not depicted). 
Second, we used a chimera between the 12 domains of 
the MHCIb molecule H-2TL (which cannot bind or present 
peptide to TCRs; Devine et al., 2002; Weber et al., 2002; 
Liu et al., 2003) and the 3 from H-2Kb, enabling normal 
CD8 binding (Attinger et al., 2005). Both KbVSV with the 
coagonism on CD8 binding to the nonstimulatory pMHCI, 
and Fig. 3 F showing the lack of F5 coagonist peptide speci-
ficity for peptides bound to the high CD8-binding affinity 
MHCI protein H-2Kb.
Minimal contribution of OT-I TCR recognition  
of nonstimulatory pMHCI to coagonism
Previous studies showed no peptide dependence for coago-
nism by nonstimulatory pMHCI, with both OT-I preselec-
tion thymocytes and peripheral T cells (Yachi et al., 2005, 
2007), nor was there any discrimination between endogenous 
nonstimulatory peptides in signaling for negative selection by 
covalent pMHC dimers containing one Kb-OVA with one 
Figure 3. The effect of CD8 affinity for coago-
nist pMHC on coagonism. Inducible sc-KbOVA  
or sc-DbNP68 CHO cells were super-transfected  
with constitutive sc-KbVSV CD8-binding mutant  
(sc-KbVSV-CD8m) or sc-DbUTY CD8-binding mutant 
(sc-DbUTY-CD8m), respectively, and used as APCs to 
assess coagonism of OT-I and F5 T cells. CHO cell 
APCs were stained for MHCI expression and in paral-
lel exposed to responder T cells whose activation 
status was measured by flow cytometry. (A) Anti-Kb 
staining of CHO cells expressing sc-MHCI. Color cod-
ing as shown in B. (B) Percentage of CD69hi OT-I  
T cells (from n = 10 individual mice) after 3-h exposure 
to the CHO APCs in A. (C) Anti-Db staining of CHO 
cells. Color coding as shown in D. (D) Percentage of 
CD69hi F5 T cells (n = 6 individual mice) after 3-h 
exposure to the CHO APCs in C. RMA-S cell were 
also used as APCs to examine coagonism of F5  
T cells. (E) Anti-Kb staining of RMA-S APCs loaded 
with combinations of NP68 agonist peptide and  
various H-2Kb–binding peptides: purple, Slc2a3;  
orange, Nmt1; green, OVA; blue, Stat3; and red, VSV.  
(F) Percentage of CD8+ F5 cells expressing CD69hi 
after 3.5-h incubation with the RMA-S cells in E (n = 4).  
A kinetic model of T cell activation reproduces the effect 
of coagonism and describes a direct relationship 
between CD8 affinity for coagonist pMHC and TCR 
phosphorylation. (G) The kinetic model discriminates 
based on antigen quality and exhibits enhanced TCR 
phosphorylation (TCRpp) in the presence of non-
stimulatory peptides. Results are shown for 10 ago-
nist peptides alone and for 10 agonist plus 90 
nonstimulatory peptides using OT-I kinetic param-
eters. (H) Results of computer simulations of the 
kinetic model describing coagonism as a function of 
CD8 affinity for nonstimulatory pMHC. Results are 
shown for F5 and OT-I kinetic parameters. Statistical 
significance (*, P < 0.05; ***, P < 0.001) results are 
from ANOVA analysis with Dunnett’s post-test, refer-
encing the repressed agonist sample (B and D) or the 
sample with agonist alone (F) as the standard. Data in 
A, C, E, and F are representative of three independent 
experiments. Data in B and D are the combined re-
sults of three independent experiments. Error bars 
represent SEM.
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To probe CD8 T cell coagonism with a similar strategy, RMA-S 
cells were first loaded with a very small amount of OVA pep-
tide followed by loading with a titration of peptides including 
the OVA-derived antagonist/positively selecting peptide R4 
(SIIRFEKL), the nonstimulatory peptide VSV (RGYVYQGL), 
and the engineered peptide poly-serine (SSYSYSSL), which 
should lack any TCR contact residues (Hogquist et al., 1994). 
Each of these peptides acted as a coagonist in an H-2Kb ex-
pression–dependent manner (Fig. 4 D), indicating that for the 
OT-I TCR, any discrimination based on the quality of the non-
stimulatory peptide is at best very small.
Reduction in CD8-binding affinity for agonist pMHCI 
enforces requirement for intact TCR interaction  
with nonstimulatory pMHC
To test the impact of CD8 affinity for agonist pMHCI on co-
agonism, we tested sc-KbOVA-CD8m (Fig. 5, A and B). As 
expected from previous work (Connolly et al., 1988, 1990; 
Potter et al., 1989), this mutation minimized direct activation 
of OT-I T cells by sc-KbOVA (Fig. 5 B and not depicted). Ac-
tivation of OT-I T cells was rescued by sc-KbVSV but not by 
E166K TCR-binding site mutation (sc-KbVSV-TCRm) and 
the TL/Kb chimera provided significant coagonism for rec-
ognition of sc-KbOVA (Fig. 4, A and B), indicating that the 
TCR interaction with nonstimulatory pMHCI was at most a 
minor determinant of coagonism for OT-I T cells. We also 
noted that recruitment of CD8 to the immunological syn-
apse (Yachi et al., 2005; Rybakin et al., 2011) was unper-
turbed by the sc-KbVSV-TCRm mutation (not depicted).
When we plotted CD69 expression data for OT-I T cells 
versus MHCI expression on CHO cells for repressed and 
induced sc-KbOVA, or repressed sc-KbOVA plus sc-KbVSV, 
we found a linear relationship (Fig. 4 C). Repressed sc-KbOVA 
plus sc-KbVSV-TCRm revealed a minor defect in coagonism 
when TCR binding to nonstimulatory pMHC was attenu-
ated. In contrast, the repressed sc-KbOVA plus the sc-KbVSV-
CD8m showed no coagonism.
A recent study showed that the OT-I TCR has a very 
weak but biologically relevant interaction with endogenous 
nonstimulatory ligands. Removal of this TCR interaction, for 
example with a peptide designed to bind Kb but to lack TCR 
interaction residues, abrogated coagonism (Juang et al., 2010). 
Figure 4. Minor contribution of OT-I TCR binding to nonstimulatory pMHC in coagonism. Inducible sc-KbOVA CHO cells were super-transfected 
with constitutive sc-KbVSV TCR-binding mutant (sc-KbVSV-TCRm) or H-2TL-Kb3 (TL/Kb) and used as APCs to assess coagonism of OT-I T cells. CHO cell 
APCs were stained for MHCI expression and in parallel exposed to responder T cells whose activation status was measured by flow cytometry. (A) CHO cell 
staining for either H-2Kb or H-2TL expression as indicated. Black indicates TL-negative staining control (Trex CHO cells). Other colors are as indicated in B. 
(B) Percentage of CD69hi OT-I T cells (n = 10 mice) after 3-h exposure to the CHO APCs in A. (C) Percentage of CD69hi OT-I T cells plotted as a function of 
the corresponding CHO APC H-2Kb expression, as indicated (n = 10 mice for CD69 data and n = 3 for H-2Kb expression on CHO cell APCs). A correction 
factor of 2.8 is applied to the H-2Kb staining of the repressed KbOVA plus KbVSV-CD8m to account for attenuated anti-Kb staining resulting from the  
CD8-binding site mutation (not depicted). RMA-S cell APCs were also used to test coagonism of OT-I T cells. (D) Percentage of CD69hi OT-I T cells plotted 
as a function of Kb expression of RMA-S cells loaded with increasing concentrations of nonstimulatory peptides R4, VSV, and SSYSYSSL, as indicated  
(n = 2 for both CD69 and H-2Kb expression). Statistical significance (*, P < 0.05; ***, P < 0.001) results are from ANOVA analysis with Dunnett’s post-test, ref-
erencing the repressed agonist sample as the standard. Data in A are representative of three independent experiments, and data in D are representative of 
two independent experiments. Data in B and C are the combined results of three independent experiments. Error bars represent SEM (B and C) or SD (D).
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binds CD8 similarly to the native H-2Kb molecule (Moody 
et al., 2001b). We therefore constructed and subsequently ex-
pressed inducible sc-KbOVA-Db3 in CHO cells and super-
transfected with sc-KbVSV or sc-KbVSV-TCRm. The altered 
3 domain epitope present in sc-KbOVA-Db3 showed at-
tenuated binding to the anti–H-2Kb antibody, visible in the 
different anti–H-2Kb staining of the induced sc-KbOVA-Db3 
versus wild-type sc-KbOVA (Fig. 5 C). The amount of H-2Kb 
sc-KbVSV-TCRm (Fig. 5 B). This was in stark contrast to 
earlier results with repressed wild-type sc-KbOVA, in which 
sc-KbVSV-TCRm was a strong coagonist (Fig. 4, B and C).
To further probe this discrepancy in coagonism by sc-
KbVSV-TCRm, we took advantage of the fact that CD8 has 
lower affinity for H-2Db than for H-2Kb (Moody et al., 2001b; 
Huang et al., 2007). The CD8-binding affinity is a property 
of the MHCI 3 domain, as a chimera of Db12-Kb3 
Figure 5. Modulation of KbOVA CD8-binding affinity and associated changes in coagonism by KbVSV-TCRm. Inducible sc-KbOVA CD8-binding 
mutant (sc-KbOVA-CD8m) CHO cells were super-transfected with constitutive sc-KbVSV or sc-KbVSV-TCRm and used as APCs to assess coagonism of 
OT-I T cells. CHO cell APCs were stained for MHCI expression and in parallel exposed to responder T cells whose activation status was measured by 
flow cytometry. (A) Anti-Kb stain of CHO cell APCs. Color coding is as shown in B. (B) Percentage of CD69hi OT-I T cells (n = 10 mice) in response to the 
CHO cell APCs in A. Inducible domain-swapped sc-KbOVA-Db3 CHO cells were also super-transfected with both sc-KbVSV or sc-KbVSV-TCRm and 
used as APCs to assess coagonism of OT-I T cells. (C) Repressed and induced KbOVA (purple and green, respectively) and KbOVA-Db3 (black and blue, 
respectively) constructs were analyzed as a function of both OVA-Kb and total H-2Kb staining, whereas repressed KbOVA plus KbVSV-TCRm (red), re-
pressed KbOVA-Db3 plus KbVSV (orange), and repressed KbOVA-Db3 plus KbVSV-TCRm (gray) were analyzed with H-2Kb staining alone. (D) CD69 
expression of CD8+ OT-I T cells responding to the APCs described in C, with color coding as in C. The horizontal black line indicates the CD69hi 
gate. (E) Percentage of CD69hi OT-I T cells (n = 4 mice) in response to the CHO cell APCs in C. (F) Calculated value of activation enhancement of 
OT-I T cells plotted as a function of anti-Kb staining of the associated CHO APCs. Repressed KbOVA plus KbVSV-TCRm and repressed KbOVA-Db3 
plus KbVSV-TCRm are shown. Statistical significance (**, P < 0.01; ***, P < 0.001) results are from ANOVA analysis with Dunnett’s post-test, refer-
encing the repressed agonist sample as the standard. Data in A are representative of three independent experiments. Data in B are the combined 
results of three independent experiments. Data in C, D, and F are representative of two experiments, whereas the data in E are the combined re-
sults from two experiments. Error bars represent SEM (B and E) or SD (F).
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sequence and MHC heavy chain. The sc-DbUTY clones used 
in our assays stained strongly with 28.14.8 but relatively 
weakly with 27.11.13 (Fig. 6 A). Linear regression analysis of 
CD69hi F5 T cells after activation with repressed sc-DbNP68, 
repressed sc-DbNP68 plus sc-DbUTY, or induced sc-DbNP68 
revealed a very strong correlation between the percentage 
of CD69hi T cells and 27.11.13 staining of the correspond-
ing CHO cells (Fig. 6 B). No such correlation existed for 
these same CD69 data plotted against 28.14.8 staining, sug-
gesting that coagonism for the F5 TCR was sensitive to the 
conformation of the 12 domains of the nonstimulatory 
pMHC and/or to the peptide presented. This result sug-
gested that there are fundamental differences in coagonism/
activation enhancement between the DbNP68-F5 and KbOVA– 
OT-I systems.
To probe the question of the specificity of coagonism of 
F5 T cells for nonstimulatory H-2Db pMHC, we screened 
a small library of 40 H-2Db–binding peptides (Table S1) 
for H-2Db binding and the ability to act as coagonists for 
F5 T cells when presented by RMA-S, identifying only two 
variant influenza peptides as coagonists (not depicted). Neither 
of these peptides (NP34, ASNENMETM; and NP371I, 
ASNENIDTM) stimulates F5 T cells (Townsend et al., 
1986; Price et al., 2000), but NP34 can act as an antagonist 
(Williams et al., 1998) and possibly so can NP371I (Price 
et al., 2000). We therefore carefully tested these peptides for 
direct activation of F5 T cells. RMA-S cells were loaded 
with 100 µM each of NP34, NP371I, and PA224 (SSLEN-
FRAYV, a Db-binding peptide which did not act as coago-
nist in our screen) or with 10 nM NP68 agonist peptide. 
H-2Db was stabilized on RMA-S cells by binding of NP34, 
NP371I, and PA224, but the H-2Db loaded with 10 nM 
NP68 agonist was undetectable (Fig. 6 C). There was no 
significant difference in T cell activation between saline-
treated RMA-S cells and those presenting high amounts of 
PA224, NP34, or NP371I on H-2Db (Fig. 6 D). RMA-S cells 
treated with 10 nM NP68 peptide activated 15% of F5 T cells. 
To test for coagonism by PA224, NP34, and NP371I, we first 
loaded RMA-S cells with 10 nM NP68 agonist, followed 
by 100 µM each of PA224, NP34, and NP371I, as previ-
ously described (Yachi et al., 2007). After peptide loading, 
these RMA-S cells expressed comparable amounts of H-2Db  
(Fig. 6 E), and when used to stimulate F5 T cells, both 
NP34 and NP371I, but not PA224, showed strong coago-
nist activity (Fig. 6 F).
Because of the positive coagonist results with sc-DbUTY–
expressing CHO cells, we also tested the ability of the UTY 
peptide to support activation enhancement when presented 
on RMA-S cells. UTY peptide loaded at 100 µM did stabi-
lize H-2Db on RMA-S cells as measured by anti-Db staining 
with antibody clone 28.14.8, but staining with the comple-
mentary anti-Db antibody 27.11.13 was negative for UTY 
but positive for NP34 and PA224 (Fig. 6, G and H). The 
fraction of F5 CD8+ T cells that up-regulated CD69 expres-
sion showed that the UTY peptide did not support activation 
enhancement (Fig. 6 I).
expression in the nonstimulatory sc-KbVSV and sc-KbVSV-
TCRm were comparable (Fig. 5 C). The CD69 expression pro-
files for OT-I CD8+ T cells (Fig. 5 D) and quantification of 
CD69hi T cells (Fig. 5 E) clearly showed the lack of statistically 
significant coagonism for sc-KbOVA-Db3 plus sc-KbVSV-
TCRm compared with either of the significant responses found 
for the sc-KbOVA-Db3 plus wild-type sc-KbVSV or wild-
type sc-KbOVA plus sc-KbVSV-TCRm.
Both repressed and induced sc-KbOVA-Db3–expressing 
CHO cells elicited systematically higher CD69 expression 
than the wild-type sc-KbOVA in the responder OT-I T cells. 
This result was unexpected, but we examined several different 
clones of the inducible sc-KbOVA-Db3 construct and each 
one behaved in a similar manner (not depicted). This phe-
nomenon could be explained by the serial TCR engagement 
model (Valitutti, 2012), which proposes that a few agonist 
pMHC complexes can initiate signaling from many TCRs. 
Optimum induction of T cell activation occurs in response to 
agonist pMHC complexes that engage TCR with intermediate 
affinity, with half-lives sufficient to initiate productive TCR 
ITAM phosphorylation but short enough to allow an indi-
vidual pMHC molecule to serially trigger several TCRs. We 
suggest that the attenuated CD8 affinity reduces the half-life 
of OT-I/CD8 engagement by KbOVA-Db3, bringing it 
closer to the optimum values that allow more effective serial 
TCR engagement and T cell activation. Because of this un-
expected result, and to explicitly show the altered behavior 
of sc-KbVSV-TCRm coagonists for the recognition of sc-
KbOVA-Db3 versus recognition of wild-type sc-KbOVA, we 
calculated the activation enhancement of OT-I T cells (percent 
CD69hi in response to repressed agonist with sc-KbVSV-TCRm 
minus percent CD69hi in response to repressed agonist alone; 
Fig. 5 F). This enabled comparison of coagonism by sc-KbVSV-
TCRm with these two different agonists, revealing that the 
nonstimulatory ligand with reduced TCR interaction provided 
greater coagonism for recognition of sc-KbOVA than for chi-
meric sc-KbOVA-Db3. The results presented in Fig. 5 sug-
gest that reduced CD8 affinity for antigenic pMHCI enforces 
an increased reliance on TCR interaction with nonstimulatory 
ligand to achieve coagonism.
Coagonist activity by H-2Db for F5 T cells requires  
TCR discrimination of nonstimulatory pMHCs
The two antibodies used to stain sc-H-2Db–transfected CHO 
cells in this study recognize different H-2Db epitopes. The 
clone 27.11.13 recognizes a peptide-dependent conforma-
tional epitope, whereas the 28.14.8 clone recognizes the H-2Db 
3 domain independent of peptide (Fig. 6 A; Palmowski et al., 
2009). We prepared sc-DbGP33 and sc-DbGP33-TCRm 
sc-MHC molecules, expressed them constitutively in CHO cells, 
and stained with both 27.11.13 and 28.14.8 anti-Db antibodies. 
These results show that the 27.11.13 antibody staining was 
diminished by the TCR-binding site mutation on H-2Db 
(Fig. 6 A). This offers strong evidence that the 27.11.13 anti-
body actually reports on the presence of amino acid residues 
that are important for TCR recognition, both in the peptide 
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Figure 6. Contribution of F5 TCR recognition of nonstimulatory H-2Db pMHC to coagonism. Inducible sc-DbNP68 CHO cells were super-transfected 
with constitutive sc-DbGP33, sc-DbGP33-TCRm, or sc-DbUTY and used either as APCs to assess coagonism of F5 T cells or as probes of anti-Db antibody speci-
ficity. (A) Dual anti-Db antibody staining (clones 28.14.8 and 27.11.13) of CHO cell APCs. (B) Percentage of CD69hi F5 T cells plotted separately versus the 
27.11.13 and 28.14.8 anti-Db stains of corresponding CHO cell APCs in A. The black lines are linear fits to the data with the R2 value for the fit reported on the 
graph (n = 6 mice). Error bars represent SEM. RMA-S cell APCs were also used to assess coagonism of F5 T cells by H-2Db–binding peptides. (C) Anti-Db stain-
ing of RMA-S APCs loaded with individual peptides. Gray shading shows RMA-S alone, and black shows RMA-S after 10 nM NP68 agonist addition. 100-µM 
additions of peptides were as follows: blue, PA224; red, NP34; and green, NP371I. (D) Percentage of CD8+CD62L+CD44lo F5 cells expressing CD69hi after 3.5-h 
incubation with the RMA-S APCs in C. (E) Anti-Db staining of RMA-S cells loaded with combinations of peptides to test coagonist activity, color coded as 
indicated in C. (F) Percentage of CD8+CD62L+CD44lo F5 cells expressing CD69hi after 3.5-h incubation with the RMA-S cells in E. (G and H) Anti-Db antibody 
staining with clones 27.11.13 (G) and 28.14.8 (H) of RMA-S cell APCs loaded with trace NP68 agonist with or without coagonists. Black indicates NP68 alone. 
100 µM additions of peptides were as follows: blue, PA224; red, NP34; and green, UTY. (I) Percentage of CD8+ F5 cells expressing CD69hi after 3.5-h incubation 
with the RMA-S cell APCs in G and H. Statistical significance (***, P < 0.001) results are from ANOVA analysis with Dunnett’s post-test, referencing the sample 
with saline (D) or agonist alone (F and I) as the standard. Data in A are representative of three independent experiments, and data in B are the combined re-
sults from three independent experiments and are the same data as presented in Figs. 2 G and 3 D. For D and F, n = 5; for I, n = 15. For RMA-S assays with 
NP34 and PA224, data are representative of six independent experiments, and for NP371I and UTY, data are representative of two independent experiments.
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pMHC. At these weak CD8 agonist pMHCI–binding affin-
ities, the lowest affinity nonstimulatory peptides provided 
little signal enhancement, and the absolute TCRpp value 
for these simulations fell below the activation threshold of 
TCRpp = 10. For the TCR with F5-like affinity for agonist 
pMHC (Fig. 7 B), there was a steeper dependence on non-
stimulatory pMHC–TCR off rate at low koff, CD8 (high CD8 
affinity) for agonist pMHC. This indicates that the kinetics of 
the TCR–agonist pMHCI interaction play a role in the re-
quirement for specific coagonists. However, at the smallest 
values of koff, CD8 for agonist pMHC, coagonism of F5 was still 
significant and the absolute values of TCRpp for the simula-
tions of agonist plus nonstimulatory peptides remained above 
the threshold of 10. For intermediate koff, CD8 for agonist 
pMHC, only the highest affinity nonstimulatory peptides 
gave any appreciable activation. At the highest values of koff, 
CD8 for agonist pMHC, the nonstimulatory pMHC gave no 
coagonism for F5. These computational results provide a con-
ceptual framework describing our experimental results, in 
which we found that CD8 affinity for agonist pMHCI is a 
key factor for the dependence of coagonism on the TCR’s 
interaction with the nonstimulatory pMHC.
DISCUSSION
Recent work has demonstrated that nonstimulatory peptides 
bound to MHC can enhance T cell recognition (Krogsgaard 
et al., 2005; Yachi et al., 2005, 2007; Anikeeva et al., 2006; 
Davis et al., 2007; Gascoigne, 2008; Gascoigne et al., 2010; 
Juang et al., 2010). To investigate the parameters of the coago-
nist phenomenon for CD8 T cells, we developed a system 
where very low expression of sc-pMHCI agonists for specific 
TCRs was coupled with constitutive expression of non-
stimulatory sc-pMHCI. Using OT-I and F5 TCRs, we tested 
combinations of H-2Kb and H-2Db, as well as mutations in 
the cognate or nonstimulatory MHC, to identify the inter-
actions important in coagonism. In addition, we used computer 
Computer simulations reveal the importance  
of TCR interaction with nonstimulatory pMHC  
when CD8 binding to agonist pMHC is weak
To provide a mechanistic context to the experimental find-
ings described here, that sensitivity of coagonism to the na-
ture of the nonstimulatory peptide originates in part from 
differences in CD8 affinity for agonist pMHCI, we modified 
the computational model described above to introduce sep-
arate koff, CD8 values for agonist and nonstimulatory pMHC 
species. This allowed us to systematically vary coreceptor 
binding affinity to agonist pMHC while keeping coreceptor 
binding to nonstimulatory pMHC constant. To test the differ-
ent requirements of OT-I and F5 T cells for nonstimulatory 
pMHC in responses to low amounts of their specific agonist 
pMHCIs, we performed simulations with agonist peptides 
only or with agonist plus nonstimulatory peptides. These sim-
ulations were performed over a range of high, intermediate, 
and low CD8 affinities for agonist pMHC (koff, CD8 for agonist 
pMHC of 50–300/s; Fig. 7 and not depicted; Cole et al., 
2012). Simulations were performed for relevant combinations 
of parameters while varying the quality of the nonstimulatory 
pMHC (koff, TCR for nonstimulatory pMHC ranging from 20/s 
to 300/s). The results are presented as the increase in TCR/
CD3 phosphorylation TCRpp,
	 ∆TCRpp TCRpp TCRppagonist nonstimulatory agonist only= −, ,  	
and color coded according to the TCRpp value of the agonist 
plus nonstimulatory peptide simulations, where TCRpp val-
ues >10 are considered activating (TCRpp denotes the mean 
number of fully phosphorylated TCR; Artyomov et al., 2010). 
The results revealed that for TCR with an OT-I–like agonist 
affinity, coagonism showed little dependence on nonstimu-
latory pMHC quality for small values of koff, CD8 for agonist 
pMHCI (i.e., high CD8 affinity; Fig. 7 A). With intermediate 
or weak CD8 binding to agonist pMHCI, however, there was 
stronger dependence on the quality of the nonstimulatory 
Figure 7. Results of computer simula-
tions of the kinetic model describing co-
agonism as a function of both TCR 
affinity for nonstimulatory pMHC and 
CD8 affinity for agonist pMHC. (A) Data 
represent simulations for an OT-I–like TCR 
affinity (modeled as kon, TCR for agonist = 
3,720/M/s and koff, TCR for agonist = 0.02/s) 
with 10 agonist and 90 nonstimulatory pep-
tides. (B) Data represent simulations for an 
F5-like TCR affinity (twofold lower affinity 
than OT-I, modeled as kon, TCR for agonist = 
72,727/M/s and koff, TCR for agonist = 0.8/s) 
with 20 agonist and 80 endogenous pep-
tides. TCRpp enhancement values were 
calculated from two different simulations for 
each point on each curve. Symbols for different CD8 agonist MHC off rates are indicated, and the curves are color coded according to the TCRpp 
value of the agonist plus nonstimulatory peptide simulations, where TCRpp values above the activation threshold of 10 (Artyomov et al., 2010) are red 
and values below that threshold are blue.
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and a second mechanism involving the affinity of CD8 for 
agonist pMHC, consistent with the experimental data de-
scribed hereafter and described by the kinetic model used 
in our study. By testing a gradient of CD8 affinities for the 
agonist sc-KbOVA, using sc-KbOVA-Db3 chimera and CD8m 
constructs, we found that the requirement for TCR recogni-
tion of the nonstimulatory sc-KbVSV became more stringent 
as the ability of CD8 to bind agonist sc-KbOVA was reduced. 
sc-KbVSV-TCRm gave slightly reduced coagonism compared 
with wild-type sc-KbVSV for agonist sc-KbOVA stimulation, 
but sc-KbVSV-TCRm coagonism for sc-KbOVA-Db3 ago-
nist was significantly reduced. sc-KbVSV-TCRm was unable 
to provide coagonism for sc-KbOVA-CD8m. Thus, loss of 
CD8 binding to sc-KbOVA introduced an absolute require-
ment for the OT-I TCR to bind to the nonstimulatory pMHC 
to drive activation, whereas weak CD8 binding to agonist re-
vealed a partial requirement for TCR recognition of the non-
stimulatory ligand.
Using the H-2Db–restricted F5 TCR and correlations 
with two different anti–H-2Db antibody–mediated measures 
of CHO H-2Db expression, the associations that we uncov-
ered suggested that coagonism of F5 cells by sc-DbUTY non-
stimulatory pMHC was dependent on the TCR interaction 
with nonstimulatory H-2Db. This requirement for TCR 
discrimination of the nonstimulatory pMHC suggests that 
coagonism for F5 recognition of DbNP68 should be more 
peptide specific than OT-I recognition of KbOVA. To further 
probe the question of peptide-specific coagonism of F5 T cells 
by nonstimulatory peptides bound to H-2Db, we used the 
RMA-S cell APC system. From a library of 40 peptides, we 
found only two H-2Db–binding peptides that acted as coago-
nists for F5 T cells. Both of these peptides were variant influ-
enza peptides, each differing in only two amino acid residues 
from the NP68 agonist. These data show that coagonism for 
F5 T cells requires TCR binding to nonstimulatory pMHC, 
where only peptides closely related to the antigen worked as 
coagonists. In contrast, as described above, when nonstimula-
tory peptides are presented to F5 T cells on H-2Kb (along 
with agonist NP68 on H-2Db), the peptide specificity of co-
agonism is lost because of the increased CD8 affinity of the 
coagonist H-2Kb pMHC (i.e., mechanism 1).
We tested the ability of the UTY peptide bound to RMA-S 
to act as a coagonist for F5 T cells. As shown in Fig. 6 I, the 
UTY peptide did not support activation enhancement of F5 
T cells when presented on RMA-S cells. However, sc-DbUTY 
expressed on CHO cells did give some degree of F5 coago-
nism. We can offer two potential explanations for this discrep-
ancy. It is possible that coagonism by sc-DbUTY results from 
the relatively high H-2Db expression on CHO compared 
with RMA-S (Fig. 6, compare A and B with G and H, for 
example) or is an artifact supplied by the single-chain design, 
for example by the presence of the stabilizing linker between 
the peptide and 2m. However, based on the 27.11.13 and 
28.14.8 anti-Db antibody correlation analysis of sc-UTY 
(Fig. 6, A and B), we concluded that an observable anti-Db 
27.11.13 antibody stain correlated with activation enhancement 
simulations of T cell activation to verify our key conclusions 
and develop a conceptual model.
Our results describe two distinct mechanisms for which 
coreceptor binding to pMHC influences the phenomenon of 
coagonism. In the first and most obvious mechanism, we find 
that CD8 affinity for the nonstimulatory pMHC exerts sev-
eral effects on coagonism. We found that both H-2Db and 
H-2Kb molecules supported coagonism but that activation 
enhancement by nonstimulatory Db ligands was less effective 
than Kb ligands for both (Kb restricted) OT-I and (Db re-
stricted) F5 T cells. This demonstrated that the phenomenon 
of coagonism is not restricted to a single MHCI molecule 
and suggested that coagonism correlated with the CD8 bind-
ing affinity for nonstimulatory MHC, as CD8 affinity for 
H-2Kb is stronger than for H-2Db (Moody et al., 2001b; 
Huang et al., 2007; Cole et al., 2012). In addition, when co-
agonist peptides were presented to F5 on H-2Kb with RMA-S 
cell APC, we found that the higher CD8 affinity for the non-
stimulatory Kb enabled coagonism to occur for all the peptides 
tested. To provide a conceptual framework within which to 
test our experimental results, we modified a kinetic model of 
T cell activation (Artyomov et al., 2010) to include nonstim-
ulatory pMHC. In stochastic computer simulations, we sys-
tematically varied the affinity of CD8 for pMHC. The results 
showed that coagonism depends on the affinity of CD8 for 
nonstimulatory pMHC, rendering our model consistent with 
experimental findings showing that higher CD8 affinity for 
nonstimulatory H-2Kb gives stronger coagonism than does the 
lower CD8 affinity for H-2Db.
The direct correlation between CD8 affinity for nonstim-
ulatory pMHC and the magnitude of coagonism suggested 
that CD8 binding to nonstimulatory pMHC is a dominant 
factor in coagonism. By introducing CD8-binding site muta-
tions (CD8m) in the 3 domains of sc-KbVSV and sc-DbUTY, 
we found that CD8 binding to nonstimulatory pMHC is an 
absolute requirement for coagonism. In the F5 system, the sc-
DbUTY-CD8m actually manifested a statistically significant 
inhibition of activation, which we interpret as competitive 
inhibition, similar to the finding that coagonist pMHCs be-
come antagonists in the absence of CD8 (Stone et al., 2011).
The requirements for the interaction of TCR with the 
nonstimulatory pMHC for coagonism are complex. For OT-I 
T cells recognizing sc-KbOVA, we detected a very mild coag-
onist defect using sc-KbVSV-TCRm as nonstimulatory pMHC. 
This defect was only clear when we accounted quantitatively 
for T cell activation as a function of total MHC expression on 
the APCs. The minimal contribution of the affinity of OT-I 
TCR for nonstimulatory pMHC to coagonism was confirmed 
by two other findings. First, the TL/Kb chimera that cannot 
bind peptide significantly enhanced activation of OT-I T cells 
and, second, that a peptide designed to have no TCR interaction 
(poly-serine; Hogquist et al., 1994) was an effective coagonist, 
similar to other nonstimulatory peptide–Kb complexes.
This complete lack of specific coagonism for OT-I T cells 
is a convolution of the relatively strong CD8 binding to 
nonstimulatory H-2Kb pMHC, mechanism 1 described above, 
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of protein mobility and modeled the relative motion of inte-
gral membrane proteins. The work presented here not only 
reveals a consistent set of requirements for CD8 and TCR-
binding affinities to the disease-related agonist and the self–
nonstimulatory pMHC complexes, but also allows us to 
formulate predictions about coagonism for systems in which 
it has not yet been systematically investigated and suggests 
explanations for some enigmatic reports in the literature. 
Mouse CD8 affinity for MHC is higher on developing thy-
mocytes than on mature CD8+ T cells (Daniels et al., 2001; 
Moody et al., 2001a), and we predict that a larger set of pep-
tides will be coagonists for thymocytes than for peripheral 
CD8+ T cells, especially for T cells bearing Db-restricted 
TCR. In addition, a study of LCMV CTL responses showed 
that H-2Db–restricted CTL numbers were decreased in H-2Kb 
knockout mice (Kotturi et al., 2008), a result which is likely 
caused by the action of mechanism 1 as described in this study, 
on both positive selection and coagonism of H-2Db–restricted 
CTL by H-2Kb–bound coagonists. More importantly, human 
CD8 affinity for HLA is generally lower than that of mouse 
CD8 for H-2 MHCI molecules (Cole et al., 2012), so we pre-
dict that during human CD8 T cell activation, only a restricted 
set of nonstimulatory peptides will support activation en-
hancement, similar to mouse CD4+ and Db-restricted CD8+ 
T cells. Moreover, several HLA alleles confer human disease 
susceptibility or protection, and the work presented here sug-
gests that different coagonism potentials of distinct MHCI 
alleles could contribute to this association.
MATERIALS AND METHODS
Plasmids. Single-chain trimer MHC KbOVA and DbNP68 (Choudhuri 
et al., 2005; Palmowski et al., 2009) were cloned into the pcDNA5/TO vec-
tor (hygromycin resistance; Invitrogen) for inducible expression of agonist. 
KbVSV (Yu et al., 2002) and the TL/Kb chimera (Attinger et al., 2005) were 
used in the pcDNA3.1 vector. Constitutive expression of DbNP68, DbUTY, 
DbUTY-YFP fusion, and DbGP33 was from the pKG4 vector backbone. 
D227K-E229K CD8-binding mutations (“CD8m”) and the E166K TCR-
binding mutation (“TCRm”) were introduced by site-directed mutagenesis. 
The 3 domain–swapped construct was made by overlap PCR. All con-
structs were prepared by Maxiprep (QIAGEN) before transfection.
Antibodies. CD8 (53-6.7), CD3 (145-2C11), V2 (B20.1), CD44 (IM7), 
CD62L (MEL-14), CD69 (H1.2F3), OVA-Kb (25.D1.16), H-2Kb (AF6-88.5), 
H-2Db (27.11.13), and H-2Db (28.14.18) were obtained from BD, eBiosci-
ence, BioLegend, or Abcam. Anti–H-2TL (18/20) was a gift of C. Lena and 
H. Cheroutre (La Jolla Institute for Allergy and Immunology, La Jolla, CA).
Mice. OT-I, OT-I Rag1/, and F5 Rag1/ mice, all on the B6 background 
(at least 10 backcross generations), were bred at the Scripps Research Insti-
tute (TSRI). F5 mice were provided by K. Walsh and M. Oldstone (TSRI). 
Protocols were approved by the Institutional Animal Care and Use Commit-
tee of TSRI.
Peptides. OVA (SIINFEKL), VSV (RGYVYQGL), UTY (WMHHNMDLI), 
and NP371I (ASNENIDTM) were obtained from Peptides International; R4 
(SIIRFEKL), poly-serine (SSYSYSSL), and NP68 (ASNENMDAM) were ob-
tained from the Scripps Peptide Core Facility; and NP34 (ASNENMETM), 
PA224 (SSLENFRAYV), and several other H-2Db–binding peptides (Table S1) 
were provided by J. Sidney and A. Sette (La Jolla Institute for Allergy and Im-
munology) or D. Popkin (TSRI). Slc2a3 (VNTFTVV), Nmt1 (AAYSFYNV), 
by the UTY peptide (Fig. 6 B). Consistent with this require-
ment, we found that H-2Db bound to UTY peptide on 
RMA-S cells did not stain with the 27.11.13 antibody but 
did stain with the 28.14.8 antibody (Fig. 6, G and H). There-
fore, based on the lack of 27.11.13 staining of RMA-S cells 
loaded with UTY peptide, we would not predict UTY to act 
as a coagonist.
The picture of mechanism 2 that emerges from the ki-
netic model is one in which activation of Lck upon TCR 
binding to agonist pMHC (Stirnweiss et al., 2013) is followed 
by this active Lck–CD8 complex finding other TCR–pMHC 
complexes in the vicinity on the cell membrane. This Lck can 
phosphorylate even short-lived complexes of TCR with non-
stimulatory pMHC that may be nearby. The kinetic model 
validated in this study suggests that agonists presented by 
MHCI with high affinity for CD8 promote a higher likeli-
hood (or effective concentration) of CD8 complexes with 
active Lck than do agonists presented by MHC molecules 
with low CD8 affinity. For coagonism to occur for weakly 
CD8-binding agonist pMHC, a longer half-life of the ternary 
TCR–nonstimulatory pMHC–CD8 complex is required 
because of the lower amount of active Lck. This increase in 
stability can be achieved with either a higher-affinity TCR–
nonstimulatory pMHC interaction or a higher-affinity CD8–
nonstimulatory pMHC interaction (i.e., mechanism 1).
Thus, the overarching principle that emerges from our 
study and from the literature is the relationship between co-
receptor affinity for pMHC and the peptide specificity of 
T cell activation. CD8 affinity for agonist pMHC plays a di-
rect role in signaling through the TCR, where increasing the 
affinity of CD8 increases ligand potency and the number 
of peptides recognized as agonists, and can even bypass pep-
tide specificity requirements altogether (Laugel et al., 2007; 
Wooldridge et al., 2007, 2010). In addition to greater cross-
reactivity, increased CD8 affinity will make a larger propor-
tion of nonstimulatory ligands potential coagonists through 
both mechanisms described here. Collectively, these data 
therefore suggest that the highest peptide specificity of T cell 
activation is achieved with MHC molecules with the lowest 
affinities for coreceptor.
Our results provide a unifying view of coagonism as these 
conclusions are also applicable to CD4 T cells, in which CD4 
affinity for MHCII is lower than CD8 affinities for MHCI 
(van der Merwe and Davis, 2003). The lower-affinity H-2Db 
MHCI agonists behave more like the previously character-
ized CD4 T cell systems, where only a very restricted set of 
coagonist peptides can support enhancement. Previously pro-
posed qualitative and mathematical models of coagonism 
studied in the context of CD4 T cells are closely related to the 
model we have studied here (Li et al., 2004; Krogsgaard et al., 
2005). These earlier calculations were modeled in the “well-
mixed” limit and did not explicitly study the mechanism by 
which active Lck coreceptor created by agonist pMHC–TCR 
complexes “found” the vicinal endogenous pMHC–TCR com-
plexes and interacted with them via the coreceptor. Here, among 
other extensions, we have explicitly included considerations 
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